CN106619702A - Drug for treating tuberculosis - Google Patents
Drug for treating tuberculosis Download PDFInfo
- Publication number
- CN106619702A CN106619702A CN201611118326.XA CN201611118326A CN106619702A CN 106619702 A CN106619702 A CN 106619702A CN 201611118326 A CN201611118326 A CN 201611118326A CN 106619702 A CN106619702 A CN 106619702A
- Authority
- CN
- China
- Prior art keywords
- parts
- treatment
- phthisical medicine
- narcotine
- piperacillin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
Abstract
The invention discloses a drug for treating tuberculosis. The drug comprises main raw materials in parts by weight: 23-27 parts of rifampicin, 10-20 parts of arabinose, 6-9 parts of artemisinin, 7-13 parts of nikethamide, 10-20 parts of solifenacin succinate, 1-2 parts of piperacillin, 8-10 parts of isosorbide dinitrate, 5-6 parts of laudanum, 1.1-1.5 parts of narcotine and 0.3-0.6 parts of potassium sulfate. The drug disclosed by the invention can be used for treating pulmonary tuberculosis efficiently and steadily in a short time, so that the anti-TB drug convenient to use and good in curative effect is provided for patients.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically one kind treat phthisical medicine.
Background technology
Pulmonary tuberculosis is the pneumonia infection disease caused by Much's bacillus, by respiratory infectious.Healthy People infects
Tulase might not fall ill, and just fall ill only when immunity of organisms declines.Pulmonary tuberculosis is a kind of chronic infection, according to pathogenic
Power, the difference of resistance of human body of virus, shows in symptom and also just differs, early stage：Feel weak, get up and compare in the morning
Tired, afternoon, performance was powerless, evening is uncontrollable excited on the contrary and cause insomnia, and become thin in the case of without other reasons,
Prolonged cough and expectoration, slowly aggravate blood-stained sputum, have difficulty in breathing, and whole body night sweat occur in sleep and WA, and
There is whole body fatigue and weakness.And there is body temperature fluctuation, occur body temperature after noon or fatigue and raise, or even low-heat, and with
Uncomfortable in chest, pectoralgia phenomenon.There is irregular menstruation or menopause in the situation without gynecological disease or pregnancy in women.When developing into hectic fever due to yin
Hectic fever and feverishness in palms and soles, face cheekbone is rubescent, dry cool drink, the red thready rapid pulse of tongue, or even lustreless complexion, and refreshing tired body is soft, and it is micro- to cough language,
Indigestion and loss of appetite loose stool, thin abundant expectoration, anemophobia spontaneous perspiration, pale tongue with white fur have indentation, a large amount of to spit blood and with cardiorespiratory failure.
Therefore, it is badly in need of a kind of suitable good effect of research and development, speed is fast, price is low, the Western medicine compound that has no toxic side effect.
The content of the invention
It is an object of the invention to provide one kind treats phthisical medicine, to solve above-mentioned background technology in propose ask
Topic.
For achieving the above object, the present invention provides following technical scheme：
One kind treats phthisical medicine, is according to the primary raw material of weight portion：Rifampin 23-27 parts, arabinose 10-
20 parts, qinghaosu 6-9 parts, nikethamidum 7-13 parts, butanedioic acid Solifenacin 10-20 parts, Piperacillin 1-2 parts, the different mountain of nitric acid
Pear ester 8-10 parts, opium tincture 5-6 parts, narcotine 1.1-1.5 parts, potassium sulfate 0.3-0.6 parts.
As further scheme of the invention：It is described to treat phthisical medicine, be according to the primary raw material of weight portion：Profit
The flat 25-27 parts of good fortune, arabinose 12-16 parts, qinghaosu 7-8 parts, nikethamidum 9-12 parts, butanedioic acid Solifenacin 13-17 parts,
Piperacillin 1-2 parts, ISDN 8-10 parts, opium tincture 5-6 parts, narcotine 1.2-1.4 parts, potassium sulfate 0.3-0.6 parts.
As further scheme of the invention：It is described to treat phthisical medicine, be according to the primary raw material of weight portion：Profit
Good fortune is flat 26 parts, 14 parts of arabinose, 8 parts of qinghaosu, 11 parts of nikethamidum, 15 parts of butanedioic acid Solifenacin, 2 parts of Piperacillin,
9 parts of ISDN, 6 parts of opium tincture, 1.3 parts of narcotine, 0.5 part of potassium sulfate.
A kind of preparation method for treating phthisical medicine, concretely comprises the following steps：
First, in pharmaceutical grade clean area, weighing by above-mentioned metering ratio can stop to rifampin, arabinose, qinghaosu, Buddhist nun
Rice, butanedioic acid Solifenacin, Piperacillin, ISDN, opium tincture, narcotine, potassium sulfate, sieve, after machinery is mixed
Addition ultra-pure water, in placing pharmacy mixer, mixes 4-8min, controls RSD≤5%, compressing tablet and low temperature drying, temperature after mixing
At 15 DEG C, packaging obtains final product the phthisical medicine for the treatment of for control.
As further scheme of the invention：Mix 6min in concrete steps.
Compared with prior art, the invention has the beneficial effects as follows：
Medicine of the present invention is efficient to the equal energy of pulmonary tuberculosis, the time is short, stable healing, and for patient a kind of user is provided
Just, eutherapeutic antimycobacterial drug.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
One kind treats phthisical medicine, is according to the primary raw material of weight portion：23 parts of rifampin, 10 parts of arabinose,
6 parts of qinghaosu, 7 parts of nikethamidum, 10 parts of butanedioic acid Solifenacin, 1 part of Piperacillin, 8 parts of ISDN, opium tincture 5
Part, 1.1 parts of narcotine, 0.3 part of potassium sulfate.
A kind of preparation method for treating phthisical medicine, concretely comprises the following steps：
First, in pharmaceutical grade clean area, weighing by above-mentioned metering ratio can stop to rifampin, arabinose, qinghaosu, Buddhist nun
Rice, butanedioic acid Solifenacin, Piperacillin, ISDN, opium tincture, narcotine, potassium sulfate, sieve, after machinery is mixed
Addition ultra-pure water, in placing pharmacy mixer, mixes 4min, controls RSD≤5%, compressing tablet and low temperature drying, temperature control after mixing
At 15 DEG C, packaging obtains final product the phthisical medicine for the treatment of to system.
Embodiment 2
One kind treats phthisical medicine, is according to the primary raw material of weight portion：25 parts of rifampin, 12 parts of arabinose,
7 parts of qinghaosu, 9 parts of nikethamidum, 13 parts of butanedioic acid Solifenacin, 1 part of Piperacillin, 8 parts of ISDN, opium tincture 5
Part, 1.2 parts of narcotine, 0.3 part of potassium sulfate.
A kind of preparation method for treating phthisical medicine, concretely comprises the following steps：
First, in pharmaceutical grade clean area, weighing by above-mentioned metering ratio can stop to rifampin, arabinose, qinghaosu, Buddhist nun
Rice, butanedioic acid Solifenacin, Piperacillin, ISDN, opium tincture, narcotine, potassium sulfate, sieve, after machinery is mixed
Addition ultra-pure water, in placing pharmacy mixer, mixes 5min, controls RSD≤5%, compressing tablet and low temperature drying, temperature control after mixing
At 15 DEG C, packaging obtains final product the phthisical medicine for the treatment of to system.
Embodiment 3
One kind treats phthisical medicine, is according to the primary raw material of weight portion：26 parts of rifampin, 14 parts of arabinose,
8 parts of qinghaosu, 11 parts of nikethamidum, 15 parts of butanedioic acid Solifenacin, 2 parts of Piperacillin, 9 parts of ISDN, opium tincture 6
Part, 1.3 parts of narcotine, 0.5 part of potassium sulfate.
A kind of preparation method for treating phthisical medicine, concretely comprises the following steps：
First, in pharmaceutical grade clean area, weighing by above-mentioned metering ratio can stop to rifampin, arabinose, qinghaosu, Buddhist nun
Rice, butanedioic acid Solifenacin, Piperacillin, ISDN, opium tincture, narcotine, potassium sulfate, sieve, after machinery is mixed
Addition ultra-pure water, in placing pharmacy mixer, mixes 6min, controls RSD≤5%, compressing tablet and low temperature drying, temperature control after mixing
At 15 DEG C, packaging obtains final product the phthisical medicine for the treatment of to system.
Embodiment 4
One kind treats phthisical medicine, is according to the primary raw material of weight portion：27 parts of rifampin, 16 parts of arabinose,
8 parts of qinghaosu, 12 parts of nikethamidum, 17 parts of butanedioic acid Solifenacin, 2 parts of Piperacillin, 10 parts of ISDN, opium tincture
6 parts, 1.4 parts of narcotine, 0.6 part of potassium sulfate.
A kind of preparation method for treating phthisical medicine, concretely comprises the following steps：
First, in pharmaceutical grade clean area, weighing by above-mentioned metering ratio can stop to rifampin, arabinose, qinghaosu, Buddhist nun
Rice, butanedioic acid Solifenacin, Piperacillin, ISDN, opium tincture, narcotine, potassium sulfate, sieve, after machinery is mixed
Addition ultra-pure water, in placing pharmacy mixer, mixes 8min, controls RSD≤5%, compressing tablet and low temperature drying, temperature control after mixing
At 15 DEG C, packaging obtains final product the phthisical medicine for the treatment of to system.
Embodiment 5
One kind treats phthisical medicine, is according to the primary raw material of weight portion：27 parts of rifampin, 20 parts of arabinose,
9 parts of qinghaosu, 13 parts of nikethamidum, 20 parts of butanedioic acid Solifenacin, 2 parts of Piperacillin, 10 parts of ISDN, opium tincture
6 parts, 1.5 parts of narcotine, 0.6 part of potassium sulfate.
A kind of preparation method for treating phthisical medicine, concretely comprises the following steps：
First, in pharmaceutical grade clean area, weighing by above-mentioned metering ratio can stop to rifampin, arabinose, qinghaosu, Buddhist nun
Rice, butanedioic acid Solifenacin, Piperacillin, ISDN, opium tincture, narcotine, potassium sulfate, sieve, after machinery is mixed
Addition ultra-pure water, in placing pharmacy mixer, mixes 8min, controls RSD≤5%, compressing tablet and low temperature drying, temperature control after mixing
At 15 DEG C, packaging obtains final product the phthisical medicine for the treatment of to system.
Comparative example 1
Rifampicin capsules, GuangDong HuaNan Pharmacy Group Co., Ltd, 0.15g mono-, three times a day, once a grain.
Comparative example 2
Isoniazid tablets, Shanghai Pharmaceutical's letter friendship pharmacy head factory, 0.1g is a piece of, three times a day, one time one
Piece.
Comparative example 3
Pyrazinamide tablet, Guangdong Taicheng Pharmaceutical Co., Ltd, 0.25g is a piece of, three times a day, one at a time.
Clinical testing
1.1 clinical data
200 Pulmonary Tuberculosis Infection patients that in June, 2015 in December, 2015 Jinan, Shandong Province medical institutions accept for medical treatment are chosen,
It is divided into a treatment group and three control groups, 50 per group, wherein all patients meet tuberculosis branch of Chinese Medical Association system
Fixed diagnosis of pulmonary tuberculosis standard, Jing iconographies and laboratory examination find activity pathology in lung.
In treatment group, the male sex 25, women 25, age 20-75 year, average age (39 ± 2.6) year, course of disease 1-5,
Average course of disease (3.6 ± 1.2) year；14 be primary pulmonary tuberculosis, 36 secondary tuberculosis of lungs；Symptom：15 patients show as
Hemoptysis symptom, 9 show as it is weak, become thin, 10 show as heating and night sweat, 8 show as pectoralgia and shortness of breath, 8 patients
Merge associativity pleurisy；Sick position：20 patient's pathologies are limited to 1 lung field, and 19 patient's pathologies are limited to two to three lung fields, and 11
Example patient's pathology is limited to four to five lung fields.
In control group, the male sex 70, women 80, age 19-73 year, average age (40 ± 2.5) year, course of disease 1-5,
Average course of disease (3.5 ± 1.0) year；46 be primary pulmonary tuberculosis, 104 secondary tuberculosis of lungs；Symptom：Wherein 52 patient's tables
Be now hemoptysis symptom, 25 show as it is weak, become thin, 33 show as heating and night sweat, and 20 show as pectoralgia and shortness of breath, 20
Example patient merges associativity pleurisy；Sick position：52 patient's pathologies are limited to 1 lung field, and 61 patient's pathologies are limited to two to three
Lung field, 34 patient's pathologies are limited to four to five lung fields；Subsequently control group is equably divided equally into three groups, reach three it is little
No significant difference between group.
The basic document of two groups of (treatment group and control group) patients, clinical symptoms and sick position scope compare, and its difference is without system
Meter learns meaning (p>0.05), there is comparativity.
1.2 treatment method
Three groups in control group, are taken respectively according to medicine disclosed in comparative example 1-3 and operation instruction.
The medicine that treatment group is prepared from the embodiment of the present invention 3, each 0.1g, three times a day.
By above scheme, control group continued treatment 1 month is 1 course for the treatment of, and treatment group continued treatment 1 month is 1 course for the treatment of, is treated
Period will monthly make regular check on the liver function of patient.After 3 courses for the treatment of, the clinical efficacy and recurrence rate of two groups of patients is observed.
1.3 efficacy determination
Cure：The cough of patient, heating, spitting blood symptom disappear, and Jing affects to learn and checks that focus is wholly absent or fiber
Change, calcification etc., in continuously turning negative, for residual cavity, sputum bacteria need to continuously turn out cloudy more than 1 year, chest the inspection of phlegm acid fast bacteria after drug withdrawal
Film inflammation patient's hydrothorax is fully absorbed；It is effective：The cough of patient, heating, spitting blood symptom disappear, and Jing imaging examinations focus absorbs bright
Aobvious, void closing was reduced more than 3 months, and the inspection of phlegm acid fast bacteria is negative；Effectively：The cough of patient, heating, spitting blood symptom disappear
Lose, Jing imaging examinations focus absorbs substantially or is not changed in, the inspection of phlegm acid fast bacteria is continuously turned negative；It is invalid：The symptom of patient does not have
There is any improvement or add and pay attention to；Deteriorate：The sputum bacteria sun of patient turns, and pathology increases, cavity increases or new cavity occurs；Recurrence：3
After the course for the treatment of terminates, if again sun turns or has new focus to occur being considered as the sputum bacteria turned out cloudy during check in a year.
Total effective rate=(recovery from illness+effective+effectively)/total number of cases * 100%.
1.4 statistical analysis carry out statistical analysis using spss13.0 statistics softwares to data, using x2Inspection is counted
Data, with P<0.05 is statistical significance standard.
2 results
After 3 courses for the treatment of terminate, treatment group has 38 healings, and 7 effective, and 4 effectively 1 invalid, 0 deterioration, and 0 multiple
Send out, total effective rate 98.0%；And control group has 7 healings, 10 effective, and 14 effectively 11 invalid, 5 deteriorations, and 3 multiple
Send out, total effective rate 62.0%.
Check after 1 year, treatment group there are 48 healings, and 2 are effective, 0 effectively 0 is invalid, 0 deterioration, 0 recurrence,
Total effective rate 100.0%；And control group has 2 healings, 4 are effective, and 5 effectively 26 are invalid, 1 deterioration, 12 recurrences,
Total effective rate 22.0%.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity those skilled in the art should
Using specification as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art
Understandable other embodiment.
Claims (5)
1. one kind treats phthisical medicine, it is characterised in that the primary raw material according to weight portion is：Rifampin 23-27 parts, Ah
Draw uncle sugar 10-20 parts, qinghaosu 6-9 parts, nikethamidum 7-13 parts, butanedioic acid Solifenacin 10-20 parts, Piperacillin 1-2 parts,
ISDN 8-10 parts, opium tincture 5-6 parts, narcotine 1.1-1.5 parts, potassium sulfate 0.3-0.6 parts.
2. the phthisical medicine for the treatment of according to claim 1, it is characterised in that the phthisical medicine of the treatment, presses
It is according to the primary raw material of weight portion：Rifampin 25-27 parts, arabinose 12-16 parts, qinghaosu 7-8 parts, nikethamidum 9-12
Part, butanedioic acid Solifenacin 13-17 parts, Piperacillin 1-2 parts, ISDN 8-10 parts, opium tincture 5-6 parts, narcotine
1.2-1.4 part, potassium sulfate 0.3-0.6 parts.
3. the phthisical medicine for the treatment of according to claim 1, it is characterised in that the phthisical medicine of the treatment, presses
It is according to the primary raw material of weight portion：26 parts of rifampin, 14 parts of arabinose, 8 parts of qinghaosu, 11 parts of nikethamidum, butanedioic acid rope
15 parts of Li Naxin, 2 parts of Piperacillin, 9 parts of ISDN, 6 parts of opium tincture, 1.3 parts of narcotine, 0.5 part of potassium sulfate.
4. a kind of preparation method of the phthisical medicine for the treatment of as described in claim 1-3 is arbitrary, it is characterised in that concrete step
Suddenly it is：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh to rifampin, arabinose, qinghaosu, nikethamidum,
Butanedioic acid Solifenacin, Piperacillin, ISDN, opium tincture, narcotine, potassium sulfate, sieve, and machinery adds after mixing
Ultra-pure water, in placing pharmacy mixer, mixes 4-8min, controls RSD≤5%, compressing tablet and low temperature drying, temperature control after mixing
At 15 DEG C, packaging obtains final product the phthisical medicine for the treatment of.
5. the preparation method of the phthisical medicine for the treatment of according to claim 4, it is characterised in that mix in concrete steps
6min。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611118326.XA CN106619702A (en) | 2016-12-07 | 2016-12-07 | Drug for treating tuberculosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611118326.XA CN106619702A (en) | 2016-12-07 | 2016-12-07 | Drug for treating tuberculosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106619702A true CN106619702A (en) | 2017-05-10 |
Family
ID=58819990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611118326.XA Pending CN106619702A (en) | 2016-12-07 | 2016-12-07 | Drug for treating tuberculosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619702A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1388758A (en) * | 2000-08-09 | 2003-01-01 | 灵药生物技术有限公司 | Pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
-
2016
- 2016-12-07 CN CN201611118326.XA patent/CN106619702A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1388758A (en) * | 2000-08-09 | 2003-01-01 | 灵药生物技术有限公司 | Pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1325083C (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN101116503A (en) | Health products for reducing blood sugar and method for preparing the same | |
| CN103405697A (en) | Medicament for treating pulmonary tuberculosis | |
| CN101785839A (en) | Traditional Chinese medicine combination and preparation method thereof for hemoptysis treatment | |
| CN104225403B (en) | One kind treats phthisical pharmaceutical composition and preparation method and purposes | |
| CN1301743C (en) | Chinese medicinal formula for treating chronic bronchitis | |
| CN107669991A (en) | A kind of pharmaceutical composition for reducing serum uric acid level and preparation method thereof | |
| CN106727547A (en) | One kind treats phthisical Western medicine combination and preparation method thereof | |
| CN106619702A (en) | Drug for treating tuberculosis | |
| CN106581048A (en) | Western medicine composition for treating tuberculosis and preparation method thereof | |
| CN104042811B (en) | Externally applied compound medicament for treating catabasis of bronchial asthma, preparation method and application thereof | |
| CN101732500A (en) | Medicine for preventing and treating acute and chronic pharyngitis and sphagitis | |
| CN106581179A (en) | Medicine for treating infiltrative pulmonary tuberculosis | |
| CN110170035B (en) | Pharmaceutical composition for treating psoriasis vulgaris, pharmaceutical preparation and application | |
| CN102441047A (en) | Traditional Chinese medicine preparation for treating iron-deficiency anemia | |
| CN104491297B (en) | A kind of Chinese medicine composition for treating palindromic urinary tract infection | |
| CN1935157B (en) | Medical stone emulsifiable paste for treating skin disease and its preparing method | |
| CN101099840A (en) | Medicine composition for treating pulmonary tuberculosis | |
| CN104491298B (en) | It is a kind of to treat Chinese medicine composition of palindromic urinary tract infection and preparation method thereof | |
| CN103251891A (en) | Chinese medicinal external-application ointment for treating qi-stagnation and blood stasis type unstable angina | |
| CN102784344B (en) | Traditional Chinese medicine preparation for treating pulmonary tuberculosis | |
| CN106668044A (en) | Western medicine composition for treating chronic bronchitis | |
| CN102813888A (en) | Chinese herbal composition for treating epilepsy | |
| CN102652821A (en) | Traditional Chinese medicine extract for treating yin deficiency and fire hyperactivity type phthisis and preparation method of traditional Chinese medicine extract | |
| CN102091155A (en) | Traditional Chinese medicine preparation for preventing and treating fatigue due to sub-health |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |
|
| RJ01 | Rejection of invention patent application after publication |